Cargando…
The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy
Introduction: Roughly one third of new non-small cell lung cancer (NSCLC) is diagnosed at early stages. While lobectomy can improve mortality in this group, about 30–55% of patients will experience disease recurrence. Increased investigation into the factors affecting recurrence, particularly tumor...
Autores principales: | Galvez, Carlos, Jacob, Saya, Finkelman, Brian S., Zhao, Jeffrey, Tegtmeyer, Kyle, Chae, Young Kwang, Mohindra, Nisha, Salgia, Ravi, Jovanovic, Borko, Behdad, Amir, Villaflor, Victoria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260116/ https://www.ncbi.nlm.nih.gov/pubmed/32523650 http://dx.doi.org/10.18632/oncotarget.27602 |
Ejemplares similares
-
Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications
por: Pathak, Ranjan, et al.
Publicado: (2021) -
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
por: Villaflor, Victoria M., et al.
Publicado: (2013) -
Lung Cancer Survival in Patients With Autoimmune Disease
por: Jacob, Saya, et al.
Publicado: (2020) -
Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
por: Novak, Jennifer, et al.
Publicado: (2022) -
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
por: Villaflor, Victoria, et al.
Publicado: (2016)